Sarah Lindberg, Sofia Sandgren, Markus Axelsson, Igal Rosenstein, Jan Lycke, Lenka Novakova
{"title":"Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.","authors":"Sarah Lindberg, Sofia Sandgren, Markus Axelsson, Igal Rosenstein, Jan Lycke, Lenka Novakova","doi":"10.1177/13524585251318516","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Reduced quality of life (QoL) is an early feature of multiple sclerosis (MS). The effect of progression independent of relapse activity (PIRA) on QoL is poorly investigated.</p><p><strong>Objective: </strong>To assess the impact of PIRA on QoL using patient-reported outcome measures (PROMs).</p><p><strong>Methods: </strong>In a prospective observational study, 125 newly diagnosed persons with relapsing-remitting MS (PwRRMS) were assessed over 5 years with: EuroQoL-5-Dimension-3-level (EQ-5D-3L), EQ-visual-analogous-scale (EQ-VAS) and 29-item-MS-Impact-Scale (MSIS-29). PwRRMS were dichotomized: PIRA (worsening of expanded disability status scale (EDSS), timed-25-foot-walk or 9-hole-peg-test, independent of relapses) versus non-PIRA. PwRRMS were compared at baseline, year 5 (y5) and delta values (baseline scores subtracted from y5 scores) and annually using linear-mixed-effects-models.</p><p><strong>Results: </strong>At y5, 19.2% had PIRA. PIRA versus non-PIRA PwRRMS were older (<i>p</i> < 0.001). At y5 PIRA PwRRMS had lower EQ-5D-3L (<i>p</i> = 0.001), higher MSIS-29-PHYS (<i>p</i> < 0.001), delta values showed lower EQ-5D-3L (<i>p</i> < 0.001) and EQ-VAS (<i>p</i> = 0.010), higher MSIS-29-PHYS (<i>p</i> = 0.004) and MSIS-29-PSYCH (<i>p</i> = 0.036). Linear-mixed-effects-models showed that, compared to PIRA, non-PIRA PwRRMS had an improvement in QoL: EQ-5D-3L: β = 0.039, <i>p</i> < 0.001; EQ-VAS: β = 2.401, <i>p</i> < 0.001; MSIS-29-PHYS: β = -0.107, <i>p</i> < 0.001; MSIS-29-PSYCH, β = -0.115, <i>p</i> < 0.001, during the 5-year study period.</p><p><strong>Conclusion: </strong>Deteriorating QoL in the early course of relapsing-remitting multiple sclerosis (RRMS) is strongly associated with PIRA. Our results suggest that QoL PROMs should be monitored and recognized as an important aspect of progression.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585251318516"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585251318516","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Reduced quality of life (QoL) is an early feature of multiple sclerosis (MS). The effect of progression independent of relapse activity (PIRA) on QoL is poorly investigated.
Objective: To assess the impact of PIRA on QoL using patient-reported outcome measures (PROMs).
Methods: In a prospective observational study, 125 newly diagnosed persons with relapsing-remitting MS (PwRRMS) were assessed over 5 years with: EuroQoL-5-Dimension-3-level (EQ-5D-3L), EQ-visual-analogous-scale (EQ-VAS) and 29-item-MS-Impact-Scale (MSIS-29). PwRRMS were dichotomized: PIRA (worsening of expanded disability status scale (EDSS), timed-25-foot-walk or 9-hole-peg-test, independent of relapses) versus non-PIRA. PwRRMS were compared at baseline, year 5 (y5) and delta values (baseline scores subtracted from y5 scores) and annually using linear-mixed-effects-models.
Results: At y5, 19.2% had PIRA. PIRA versus non-PIRA PwRRMS were older (p < 0.001). At y5 PIRA PwRRMS had lower EQ-5D-3L (p = 0.001), higher MSIS-29-PHYS (p < 0.001), delta values showed lower EQ-5D-3L (p < 0.001) and EQ-VAS (p = 0.010), higher MSIS-29-PHYS (p = 0.004) and MSIS-29-PSYCH (p = 0.036). Linear-mixed-effects-models showed that, compared to PIRA, non-PIRA PwRRMS had an improvement in QoL: EQ-5D-3L: β = 0.039, p < 0.001; EQ-VAS: β = 2.401, p < 0.001; MSIS-29-PHYS: β = -0.107, p < 0.001; MSIS-29-PSYCH, β = -0.115, p < 0.001, during the 5-year study period.
Conclusion: Deteriorating QoL in the early course of relapsing-remitting multiple sclerosis (RRMS) is strongly associated with PIRA. Our results suggest that QoL PROMs should be monitored and recognized as an important aspect of progression.
期刊介绍:
Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system.
The journal for your research in the following areas:
* __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics
* __Epidemology and genetics:__ genetics epigenetics, epidemiology
* __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures
* __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management
Print ISSN: 1352-4585